Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

31 questions · 32 findings · 11 reviews

No studies found 1 · 3.1%GRADE not reported 1 · 3.1%Very low 16 · 50%Low 9 · 28.1%Moderate 4 · 12.5%High 1 · 3.1%

Delayed chemotherapy vs immediate chemotherapy

Toxicity – diarrhoea · patients with asymptomatic, incurable, metastatic colorectal cancer

It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).

1 finding from 1 review

Delayed chemotherapy vs immediate chemotherapy

Toxicity – stomatitis · patients with asymptomatic, incurable, metastatic colorectal cancer

It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).

1 finding from 1 review

Chemotherapy (any regimen; added to, or compared with, locoregional treatment) vs Locoregional treatment and/or an alternative chemotherapy regimen

Toxicity / adverse effects (harms) of chemotherapy · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review

Delayed chemotherapy vs immediate chemotherapy

Nausea and vomiting · patients with asymptomatic, incurable, metastatic colorectal cancer

It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).

1 finding from 1 review

Combination chemotherapy vs single‐agent chemotherapy

Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).

1 finding from 1 review

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

ATRA in addition to chemotherapy vs chemotherapy alone

Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))

It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).

1 finding from 1 review

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).

2 findings from 1 review

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).

1 finding from 1 review

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).

1 finding from 1 review